FDA Streamlines Nonclinical Studies for Biologics and Conjugated Products, Accepting NAMs for ADCs to Reduce Non-Human Primate Use

FDA USA

Overview

The FDA’s Center for Drug Evaluation and Research (CDER) is streamlining nonclinical studies for biologics and conjugated products, including Antibody-Drug Conjugates (ADCs) and CD3 bispecific T-cell engagers. For ADCs with well-characterized cytotoxic payloads, 3-month toxicology studies may now be conducted in rodents only, potentially reducing the use of non-human primates. This guidance aims to optimize nonclinical safety assessments and accelerate drug development while maintaining safety standards.

In Depth

Key Findings

The U.S. FDA’s Center for Drug Evaluation and Research (CDER) has announced a new initiative to streamline nonclinical studies for biologics and conjugated products. This policy expands the acceptance of New Approach Methodologies (NAMs) for advanced modalities, including Antibody-Drug Conjugates (ADCs) and CD3 bispecific T-cell engagers.

Technical / Clinical Details

CDER’s updated guidance offers flexibility in the nonclinical safety assessment requirements for specific biologics and conjugated products. Notably, for ADCs with well-characterized cytotoxic payloads, the traditional 3-month general toxicology studies, which typically involved both rodent and non-rodent (often non-human primate) species, may now be permitted in rodents only. This change is poised to significantly reduce the use of non-human primates, fostering animal welfare, and substantially improving the speed and cost-efficiency of preclinical development. NAMs encompass a range of innovative tools, including in vitro assays, computational toxicology models, organoids, and human-on-chip devices, all utilized to predict potential drug toxicities and pharmacokinetics earlier and more accurately. CDER’s stance is that these new methodologies can complement or even replace conventional animal testing data, provided they meet criteria for reliability, relevance, and reproducibility. This streamlining is expected to have ripple effects across the rapidly evolving biopharmaceutical sector, including cell and gene therapies and biosimilars.

Background & Context

Drug development, particularly for complex biologics, is notoriously expensive and time-consuming. Nonclinical studies are essential for establishing a drug’s safety profile before human administration, yet the ethical implications of animal testing and questions regarding their correlation with human responses have long been debated. Recent scientific and technological advancements have led to the development and validation of NAMs that can either complement or replace traditional animal tests. The FDA’s decision aligns with international regulatory trends that promote the 3R principles (Replacement, Reduction, Refinement), encouraging a more efficient and ethical drug development process. For pharmaceutical companies, this represents an opportunity to realize multiple benefits: shortened development timelines, reduced costs, and enhanced commitment to animal welfare.

Strategic Significance & Outlook

This new FDA approach is expected to significantly reshape how nonclinical evaluations are conducted in future drug development. The expanded acceptance of NAMs will further accelerate the development of in silico toxicity prediction models leveraging AI and machine learning, paving the way for more innovative therapies to reach patients faster. Moving forward, CDER is likely to further clarify the applicability of NAMs across specific product classes and disease areas, supporting pharmaceutical companies in effectively adapting to the new guidelines. This will substantially contribute to achieving the goals of accelerating new drug market entry, minimizing the burden of animal testing, all while maintaining high standards of safety and efficacy. This initiative will also closely interact with advancements in DDS technologies, driving the development of safer and more efficient drug delivery systems.